Q1 Earnings Estimate for Altimmune Issued By B. Riley

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Altimmune in a report issued on Wednesday, November 13th. B. Riley analyst M. Mamtani anticipates that the company will earn ($0.41) per share for the quarter. B. Riley currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune’s FY2025 earnings at $0.73 EPS.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the business posted ($0.39) EPS.

ALT has been the topic of a number of other research reports. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday. Finally, UBS Group initiated coverage on Altimmune in a research note on Tuesday. They set a “buy” rating and a $26.00 target price for the company. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Price Performance

NASDAQ ALT opened at $9.52 on Thursday. Altimmune has a 1-year low of $2.34 and a 1-year high of $14.84. The firm has a market capitalization of $676.59 million, a P/E ratio of -6.14 and a beta of 0.09. The business’s 50-day simple moving average is $6.95 and its 200-day simple moving average is $6.89.

Hedge Funds Weigh In On Altimmune

Several large investors have recently bought and sold shares of ALT. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Altimmune in the 1st quarter worth $271,000. BNP Paribas Financial Markets boosted its position in shares of Altimmune by 154.0% in the 1st quarter. BNP Paribas Financial Markets now owns 32,425 shares of the company’s stock valued at $330,000 after purchasing an additional 19,661 shares during the period. SG Americas Securities LLC increased its stake in Altimmune by 68.3% in the 1st quarter. SG Americas Securities LLC now owns 39,603 shares of the company’s stock worth $403,000 after purchasing an additional 16,078 shares in the last quarter. Swiss National Bank acquired a new stake in Altimmune during the 1st quarter worth about $1,079,000. Finally, Sei Investments Co. purchased a new stake in Altimmune during the first quarter valued at about $479,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Insiders Place Their Bets

In other Altimmune news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is currently owned by corporate insiders.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.